Erectile Dysfunction Devices Market Size and Share
Erectile Dysfunction Devices Market Analysis by Mordor Intelligence
The erectile dysfunction devices market is valued at USD 1.88 billion in 2025 and is forecast to advance to USD 2.95 billion by 2030, registering a 9.40% CAGR during the period. Rising dissatisfaction with oral phosphodiesterase-5 inhibitors, which show more than 40% real-world non-response, accelerates patient migration toward mechanical or implantable therapies. Device makers are also benefiting from younger-onset prevalence trends, expanded post-prostatectomy protocols, and streamlined tele-prescription rules that support at-home therapy initiation. Concurrently, hospital cost-containment imperatives push outpatient centers to adopt minimally invasive techniques, improving operating margins for providers while preserving quality outcomes. On the supply side, manufacturers are re-engineering bill-of-materials to reduce exposure to silicone shortages and to comply with new vacuum device pressure-range coding, strengthening production resilience.
Key Report Takeaways
- By device type, penile implants led with 52.35% of erectile dysfunction devices market share in 2024, whereas low-intensity shockwave systems are projected to expand at a 12.25% CAGR through 2030.
- By cause, vascular disorders accounted for 60.53% share of the erectile dysfunction devices market size in 2024; neurological causes show the highest forecast CAGR at 10.85% to 2030.
- By end user, hospitals commanded 46.82% of 2024 revenue, but ambulatory surgery centers are advancing at a 10.61% CAGR through 2030.
- By geography, North America captured 41.82% of 2024 revenue, while Asia-Pacific is on track for an 11.52% CAGR through 2030.
Global Erectile Dysfunction Devices Market Trends and Insights
Drivers Impact Analysis
Driver | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
---|---|---|---|
Growing prevalence of erectile dysfunction | +2.1% | Global, with highest concentration in North America and Europe | Long term (≥ 4 years) |
Increasing post-prostatectomy rehabilitation demand | +1.8% | North America and Europe, emerging in Asia-Pacific | Medium term (2–4 years) |
Rise in R&D and FDA approvals for next-gen ED devices | +1.5% | Global, led by US and EU regulatory pathways | Medium term (2–4 years) |
High dissatisfaction with oral ED drugs | +1.4% | Global, particularly in developed markets | Short term (≤ 2 years) |
Tele-prescription laws enabling at-home VED adoption | +1.2% | North America, expanding to Europe and Asia-Pacific | Short term (≤ 2 years) |
Mini-incision IPP techniques cutting cost and LOS | +0.9% | Global, early adoption in North America | Medium term (2–4 years) |
Source: Mordor Intelligence |
Growing Prevalence of Erectile Dysfunction
Post-COVID vascular sequelae further swell the candidate pool, while Google Trends heat-maps uncover high search density in underserved counties, signalling pent-up demand[1]Tingrui Pan, “A Wearable Adaptive Penile Rigidity Monitoring System,” Nature Microsyst Nanoeng, doi.org. Manufacturers respond with culturally sensitive campaigns and discreet wearables, which appeal to younger users seeking reversible solutions. The demographic expansion underpins sustained double-digit unit growth across vacuum and wearable categories within the erectile dysfunction devices market. Momentum is unlikely to ebb as social attitudes toward men’s sexual health continue to liberalize in Asia-Pacific and South America.
Increasing Post-Prostatectomy Rehabilitation Demand
Roughly 58% of radical prostatectomy patients experience erectile dysfunction within two years, a statistic that is reshaping perioperative pathways. Simultaneous penile prosthesis and artificial urinary sphincter placement now supersedes staged procedures, cutting anesthesia time and boosting satisfaction indices. Vacuum erection devices (VEDs) serve as first-line rehabilitation in combination with phosphodiesterase inhibitors, elevating International Index of Erectile Function (IIEF-5) scores faster than pharmacotherapy alone. Medicare and private insurers increasingly reimburse these multimodal pathways, a trend likely to widen adoption beyond high-volume centers.
Rise in R&D and FDA Approvals for Next-Gen ED Devices
The 2024-2025 FDA docket lists multiple 510(k) clearances, including the rechargeable EDP MAX Rc erection device, signaling rapid design-refresh cycles. Boston Scientific’s TENACIO pump adds independent valving and a 27% faster refill rate, marking the biggest implant upgrade in a decade. Alongside implants, AI-enabled diagnostic wearables like the WARM system substitute cumbersome RigiScan tests with real-time rigidity analytics. These innovations funnel venture capital into the erectile dysfunction devices industry and open premium-priced niches that lift average selling prices.
High Dissatisfaction with Oral ED Drugs
Clinical meta-analyses show that 40% of men derive insufficient benefit from phosphodiesterase inhibitors, a gap most common in severe vascular or diabetic cohorts. Out-of-pocket costs amplify the discontent; Medicare modelling pegs annual therapy at USD 696 for sildenafil versus a one-time USD 1,600 co-pay for an inflatable prosthesis over a 10-year life. Physicians therefore escalate to mechanical options sooner, and start-ups pitch discreet wearables that circumvent systemic side-effects, accelerating share gains for the erectile dysfunction devices market.
Restraints Impact Analysis
Restraint | (~) % Impact on CAGR Forecast | Geographic Relevance | Impact Timeline |
---|---|---|---|
Availability of pharmacologic alternatives | -1.6% | Global, strongest where generic PDE5 access is high | Long term (≥ 4 years) |
Social stigma and low patient awareness | -1.3% | Asia-Pacific and Middle East, declining in West | Medium term (2–4 years) |
Supply-chain fragility in medical-grade silicone | -0.8% | Global manufacturing, heavily Asian hubs | Short term (≤ 2 years) |
Reimbursement downgrades for shockwave therapy | -0.7% | North America and Europe | Medium term (2–4 years) |
Source: Mordor Intelligence |
Availability of Pharmacologic Alternatives
Low-priced generics and mail-order telehealth platforms such as Roman and BlueChew prolong pill dominance in cost-sensitive cohorts[2]Lisa Catanese, “Need a Prescription for an ED Medication?,” Harvard Health, health.harvard.edu. Nasal and topical pipelines add formulation diversity and could stall device conversion rates. Even so, Viatris’ 2024 discontinuation of alprostadil urethral suppositories leaves a therapy void that favors vacuum systems and intracavernosal injections.
Social Stigma & Low Patient Awareness
Attitudinal surveys show 53.1% of Saudi respondents avoid medical advice for erectile dysfunction due to embarrassment, underscoring a continuing education gap. Telemedicine mitigates face-to-face discomfort and nudges uptake, but manufacturers must fine-tune messaging to cultural norms to unlock Asia-Pacific headroom.
Segment Analysis
By Device Type: Implants Lead Innovation Wave
Penile implants retained 52.35% revenue in 2024 and generated the majority of the erectile dysfunction devices market size attributed to surgical solutions. The latest AMS 700 with TENACIO pump shortens inflation cycles and delivers 10-year durability, features that pushed 2025 unit demand up by double digits in U.S. centers. Such improvements signal why implants still dominate a crowded field of vacuums, wearables, and shockwave consoles. Growth, however, now tilts toward non-invasive categories: low-intensity shockwave platforms logged a 12.25% CAGR and are popular in multidisciplinary men’s-health clinics where physicians package the therapy with platelet-rich plasma injections to lift response rates[3]Rajesh Kumar et al., “Low-Intensity Shockwave Therapy Long-Term Outcomes,” PubMed Central, pmc.ncbi.nlm.nih.gov.
Vacuum constriction cylinders, newly coded under 2025 HCPCS guidelines, enjoy reimbursement clarity that widens payer coverage. Wearables such as Eddie by Giddy achieved FDA registration and posted 88.9% pain-free intercourse scores in a 2024 survey, crowding the niche for mild-to-moderate cases. These varied modalities collectively ensure that the erectile dysfunction devices market remains technologically pluralistic.
Note: Segment shares of all individual segments available upon report purchase
By Cause of Dysfunction: Vascular Dominance Drives Innovation
In 2024, vascular etiologies represented 60.53% of therapy volume, underscoring cardiovascular comorbidity as the prime target of emerging gadgets. Shockwave consoles promote neovascularization and yielded a 69% minimal clinically important difference in African trial cohorts three months post-treatment. The erectile dysfunction devices market size for vascular cases will deepen as diabetic and hypertensive patients flow into care pathways. Meanwhile, neurological causes are expanding at 10.85% CAGR, owing to post-COVID neuropathies that lengthen waitlists for specialized neuro-urology consults.
PNAS-reported microrobot technology, which ferries mesenchymal stromal cells directly into cavernous tissue, promises a regenerative alternative that could disrupt vascular and neurogenic treatment algorithms. Psychogenic categories also benefit from AI-assisted decision tools that elevate diagnostic accuracy, guiding clinicians toward bespoke device selections.
By End User: Ambulatory Centers Accelerate Growth
Hospitals accounted for 46.82% revenue in 2024, yet the shift to outpatient settings is unmistakable. Minimally invasive infrapubic approaches reduced infection rates to 0% in straightforward cases, enabling same-day discharge and catalyzing a 10.61% CAGR for ambulatory surgery centers. Clinics and physician-owned offices ride the telehealth wave by bundling vacuum or shockwave packages with virtual follow-up, giving them a cost edge relative to tertiary hospitals. Such dynamics realign value capture within the erectile dysfunction devices market, rewarding providers that can compress operating time while sustaining outcomes.

Note: Segment shares of all individual segments available upon report purchase
Geography Analysis
North America remains the fulcrum of revenue, holding 41.82% in 2024 on the back of robust payer frameworks and an installed base of high-volume urologists. Boston Scientific’s interventional urology sales hit USD 633 million in Q1 2025, with erectile prostheses a core component. The region’s clinicians increasingly bypass staged prosthesis-sphincter surgeries, further expanding procedure counts.
Asia-Pacific, however, is the fastest climber at 11.52% CAGR. Japanese retrospective studies validate next-gen vacuums, while China’s domestic producers of silicone reservoirs shrink import reliance. Medical tourism to Turkey, where Coloplast Titan procedures average EUR 10,000, attracts European and Middle Eastern patients seeking price relief. Together, these dynamics are enlarging regional slices of the erectile dysfunction devices market.
Europe exhibits mid-single-digit growth as MDR roll-outs stabilize and payer reviews temper shockwave reimbursements. Key markets such as Germany still fund implants for severe cases, sustaining baseline demand. Latin America and the Middle East are in earlier adoption cycles but benefit from improving cultural openness and international provider partnerships, positioning them as long-term contributors.

Competitive Landscape
The erectile dysfunction devices industry shows moderate concentration. Boston Scientific, Coloplast, and Rigicon control majority of implant unit shipments yet face insurgent wearable and shockwave entrants. Boston Scientific’s USD 3.7 billion acquisition of Axonics broadens its pelvic health continuum, allowing cross-selling into overactive bladder and fecal incontinence pathways. Coloplast’s Titan line secured 5% growth in FY 2024 despite raw-material inflationary pressure that squeezed margins.
Rigicon differentiates through complex-case ergonomics and collagen fleece grafting techniques that restore curvature, earning surgeon loyalty in tertiary referral centers. Start-ups like Ohh-Med and Reach Medical chase non-invasive niches with upgraded wearables and rechargeable vacuums, both benefiting from direct-to-consumer channels. Supply-chain continuity emerges as a battleground; firms investing in dual-source silicone molding or additive-manufactured reservoirs incur lower back-order risk during global shortages.
Erectile Dysfunction Devices Industry Leaders
-
Coloplast Group
-
Rigicon, Inc.
-
Boston Scientific Corporation
-
Promedon GmBH
-
Zephyr Surgical Implants
- *Disclaimer: Major Players sorted in no particular order

Recent Industry Developments
- November 2024: Boston Scientific launches the TENACIO pump as part of its AMS 700 IPP system, offering a 27% faster refill and independent valve action.
- June 2024: Ohh-Med unveils an ergonomically enhanced wearable erectile dysfunction device to improve user comfort.
Global Erectile Dysfunction Devices Market Report Scope
As per the scope of the report, erectile dysfunction devices are medical tools designed to help men achieve and maintain an erection. These devices can either be surgically implanted or are external pumps that create a vacuum around the penis. The erectile dysfunction devices market is segmented by device type, cause of the dysfunction, end user and geography. The device type segment is further divided into penile implants, vacuum constriction devices, shockwave therapy, and other device types. The cause of the dysfunction segment is further segmented into vascular disorders, neurological disorders, and other causes. The End User segment is further bifurcated into hospitals, clinics, and ambulatory surgical centers. The geography segment is further bifurcated into North America, Europe, Asia-Pacific, Middle East and Africa, and South America. The report offers the value (in USD) for the above segments.
By Device Type | Penile Implants | |
Vacuum Constriction Devices (VED) | ||
Shockwave Therapy Systems | ||
Other Device Types | ||
By Cause of Dysfunction | Vascular Disorder | |
Neurological Disorder | ||
Other Causes | ||
By End User | Hospitals | |
Clinics & Specialty Centers | ||
Ambulatory Surgery Centers | ||
Geography | North America | United States |
Canada | ||
Mexico | ||
Europe | Germany | |
United Kingdom | ||
France | ||
Italy | ||
Spain | ||
Rest of Europe | ||
Asia-Pacific | China | |
Japan | ||
India | ||
South Korea | ||
Australia | ||
Rest of Asia-Pacific | ||
Middle East and Africa | GCC | |
South Africa | ||
Rest of Middle East and Africa | ||
South America | Brazil | |
Argentina | ||
Rest of South America |
Penile Implants |
Vacuum Constriction Devices (VED) |
Shockwave Therapy Systems |
Other Device Types |
Vascular Disorder |
Neurological Disorder |
Other Causes |
Hospitals |
Clinics & Specialty Centers |
Ambulatory Surgery Centers |
North America | United States |
Canada | |
Mexico | |
Europe | Germany |
United Kingdom | |
France | |
Italy | |
Spain | |
Rest of Europe | |
Asia-Pacific | China |
Japan | |
India | |
South Korea | |
Australia | |
Rest of Asia-Pacific | |
Middle East and Africa | GCC |
South Africa | |
Rest of Middle East and Africa | |
South America | Brazil |
Argentina | |
Rest of South America |
Key Questions Answered in the Report
What is the growth rate of the erectile dysfunction devices market from 2025 to 2030?
The market is projected to expand at a 9.40% CAGR, climbing from USD 1.88 billion in 2025 to USD 2.95 billion in 2030.
Which device type currently holds the largest market share?
Penile implants lead with 52.35% of 2024 revenue, buoyed by innovations such as Boston Scientific’s TENACIO pump.
Which region is expected to grow the fastest through 2030?
Asia-Pacific is forecast to post the highest regional CAGR at 11.52%, driven by stronger healthcare infrastructure and diminishing cultural barriers.
Why are more patients moving from oral ED drugs to devices?
Around 40% of users do not respond adequately to PDE5 inhibitors and face rising out-of-pocket costs, so many shift to mechanical or implantable options for reliable results.
What fuels the rapid growth of ambulatory surgery centers in this market?
Mini-incision and no-touch implant techniques enable same-day discharge, propelling ambulatory centers to a 10.61% CAGR as procedures migrate from hospitals.
Page last updated on: